← Back to Screener
Inotiv, Inc. Common Stock (NOTV)
Price$0.30
Favorite Metrics
Price vs S&P 500 (26W)-78.35%
Price vs S&P 500 (4W)-2.21%
Market Capitalization$12.90M
All Metrics
Book Value / Share (Quarterly)$3.17
P/TBV (Annual)29.75x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.16%
Cash Flow / Share (Quarterly)$-0.84
Price vs S&P 500 (YTD)-33.33%
Gross Margin (TTM)23.49%
Net Profit Margin (TTM)-13.50%
EPS (TTM)$-2.02
10-Day Avg Trading Volume1.27M
EPS Excl Extra (TTM)$-2.02
Revenue Growth (5Y)53.35%
EPS (Annual)$-2.11
ROI (Annual)-12.61%
Gross Margin (Annual)23.58%
Net Profit Margin (5Y Avg)-20.64%
Cash / Share (Quarterly)$0.37
Revenue Growth QoQ (YoY)0.84%
ROA (Last FY)-8.90%
Revenue Growth TTM (YoY)8.19%
EBITD / Share (TTM)$0.69
ROE (5Y Avg)-47.25%
Operating Margin (TTM)-6.17%
Cash Flow / Share (Annual)$-0.79
P/B Ratio0.12x
P/B Ratio (Quarterly)0.18x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.81x
Net Interest Coverage (TTM)-0.55x
ROA (TTM)-9.15%
EV / EBITDA (TTM)17.44x
EPS Incl Extra (Annual)$-2.11
Current Ratio (Annual)0.35x
Quick Ratio (Quarterly)0.20x
3-Month Avg Trading Volume0.56M
52-Week Price Return-74.86%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.57
P/S Ratio (Annual)0.03x
Asset Turnover (Annual)0.67x
52-Week High$3.32
Operating Margin (5Y Avg)-18.44%
EPS Excl Extra (Annual)$-2.11
CapEx CAGR (5Y)21.79%
Tangible BV CAGR (5Y)11.54%
26-Week Price Return-74.37%
Quick Ratio (Annual)0.23x
13-Week Price Return-36.98%
Total Debt / Equity (Annual)3.00x
Current Ratio (Quarterly)0.30x
Enterprise Value$414.747
Revenue / Share Growth (5Y)23.29%
Asset Turnover (TTM)0.68x
Book Value / Share Growth (5Y)41.79%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)12.27x
Pretax Margin (Annual)-17.11%
Cash / Share (Annual)$0.63
3-Month Return Std Dev167.67%
Gross Margin (5Y Avg)27.51%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)87.43%
ROE (Last FY)-50.45%
Net Interest Coverage (Annual)-0.56x
EPS Basic Excl Extra (Annual)$-2.11
P/FCF (TTM)1.11x
Receivables Turnover (TTM)7.71x
Total Debt / Equity (Quarterly)3.80x
EPS Incl Extra (TTM)$-2.02
Receivables Turnover (Annual)6.76x
ROI (TTM)-12.78%
P/S Ratio (TTM)0.03x
Pretax Margin (5Y Avg)-24.60%
Revenue / Share (Annual)$15.81
Tangible BV / Share (Annual)$0.57
Price vs S&P 500 (52W)-104.69%
Year-to-Date Return-30.69%
5-Day Price Return68.95%
EPS Normalized (Annual)$-2.11
ROA (5Y Avg)-13.33%
Net Profit Margin (Annual)-13.38%
Month-to-Date Return42.97%
Cash Flow / Share (TTM)$-10.97
EBITD / Share (Annual)$0.76
Operating Margin (Annual)-6.02%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-18.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.02
P/TBV (Quarterly)29.75x
P/B Ratio (Annual)0.37x
Inventory Turnover (TTM)10.37x
Pretax Margin (TTM)-17.12%
Book Value / Share (Annual)$3.96
Price vs S&P 500 (13W)-37.67%
Beta4.21x
P/FCF (Annual)33.94x
Revenue / Share (TTM)$14.96
ROE (TTM)-50.77%
52-Week Low$0.22
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.13
4.13
4.13
Industry Peers — R&D — Physical Sciences(9)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.30 |
IQVIQVIA Holdings Inc. | 22.22x | 22.28% | 7.50% | — | $171.95 |
INCYIncyte Genomics Inc | 14.67x | 29.15% | 14.03% | — | $95.32 |
MEDPMedpace Holdings, Inc. Common Stock | 32.83x | 118.82% | 22.27% | — | $515.65 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $176.94 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.23 |
NRCNational Research Corporation Common Stock (Delaware) | 34.98x | 58.51% | 0.61% | 3.59% | $17.62 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.56 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.82 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.12 |
About
Inotiv provides nonclinical and analytical drug development services to pharmaceutical, chemical, and medical device companies. Operating through two segments—Discovery and Safety Assessment and Research Models and Services—the company supports small molecule and biologic drug discovery while supplying specialized research models for disease-specific applications. The Research Models and Services segment generates the majority of revenue.